王小晟

发布者：陈洁洋发布时间：2016-03-14浏览次数：6692

 王小晟，中国药科大学副教授，博士生导师，浙江大学医学院康复医学研究中心专家委员会委员。日本京都大学生物信息学博士。美国国立卫生研究院(NIH)博士后，美国内布拉斯加大学医学中心(UNMC)讲师。主要研究兴趣为生物信息学、医学基因组学、肿瘤免疫治疗、系统生物学、生物统计学。

  作为主要贡献者已在Journal of Medical Virology (IF=20.693, 独立通讯作者)、Briefings in Bioinformatics (IF=13.994, 独立通讯)、Journal of Experimental & Clinical Cancer Research (IF=12.658, 独立通讯)、Journal for ImmunoTherapy of Cancer (IF=12.469, 独立通讯)、EBioMedicine (IF=11.205, 独立通讯)、Science of The Total Environment (IF=10.753, 独立通讯)、Infectious Diseases of Poverty (IF=10.485, 独立通讯)、npj Precision Oncology (IF=10.092, 独立通讯)、Journal of Neuroinflammation (IF=9.587, 独立通讯)、Frontiers in Immunology (IF=8.786, 独立或第一通讯)、Clinical and Translational Medicine (IF=8.554, 独立通讯)、Journal of Translational Medicine (IF=8.440, 独立或第一通讯)、Computers in Biology and Medicine(IF=7.7, 独立通讯)、Cellular Oncology (IF=7.051, 独立通讯)、Communications Biology (IF=6.548, 独立通讯)、Computational and Structural Biotechnology Journal (IF=6.155, 独立或第一通讯)等杂志发表SCI论文100余篇，获软件专利2项。现任Heliyon, Scientific Reports, Frontiers in Genetics, the World Journal of Gastrointestinal Oncology, Journal of Clinical Medicine等国际杂志编委,The Lancet Respiratory Medicine, Journal of the National Cancer Institute, Nucleic Acids Research, Journal for ImmunoTherapy of Cancer, EBioMedicine, npj Precision Oncology, MED等国际杂志审稿专家，The European Research Council (ERC) Consolidator 基金，Swiss National Science Foundation (SNSF) 基金和The Israel Science Foundation (ISF) 基金评审专家。

近年来有影响的代表性学术成果：

1. 由于在肿瘤免疫基因组方面的研究获邀在2019年九月日本举行的The 78th Annual Meeting of the Japanese Cancer Association的国际分会作特邀报告。

2. 发现了与肿瘤免疫和肿瘤免疫治疗反应的相关标志物，包括基因（TP53﹑ARID1A、KALRN、PLK1、HRAS 和 HIF1A）和通路（cell cycle、 glycolysis、neurotrophin, spliceosome）标志物，已发表10余篇相关论文。

3. 开发了一个基于肿瘤细胞转录组改变的异步性（asynchrony）定义肿瘤内异质性（intratumor heterogeneity）的算法DEPTH, 并且证明了DEPTH在评估肿瘤异质性方面较其它算法具有相当的优越性，该研究已经被媒体报道，链接为：

https://mbd.baidu.com/newspage/data/landingshare?context=%7B%22nid%22%3A%22news_10559135977396967716%22%7D&isBdboxFrom=1&pageType=1&rs=3477249731&ruk=AGoutMNu4-wkOG1DdpOS0g。

4. 提出了一种基于免疫信号基因集打分的非监督机器学习方法，对肿瘤进行免疫分类，该方法可用于标识适合免疫治疗的肿瘤子类型，已经被许多研究者所采用，相关论文已经在Google学术被引用超350次。

5. 第一个系统地研究了p53突变与肿瘤免疫性在各种不同肿瘤类型的关联，发现p53突变在某些肿瘤类型增强了肿瘤免疫性，在一些其它的肿瘤类型抑制了肿瘤免疫性，揭示了造成这种差别的主要原因为p53突变对基因组不稳定的影响在这些肿瘤类型存在差别，已发表相关论文4篇。

6. 开发了“癌症组学图谱数据库”软件为国内外学术界广泛使用，该数据库链接为：https://tcoa.cpu.edu.cn/，数据库已经被访问超过43万次。

7. 第一个系统地分析了新冠病毒受体基因ACE2在各种人类正常组织器官﹑病毒感染的组织及肿瘤组织的表达情况，为新冠病毒感染人类除肺以外的各种组织器官提供了理论基础；第一个揭示了ACE2是一个阻止肿瘤进展的潜在保护性因子，ACE2可促进肿瘤免疫治疗反应。已发表相关论文3篇，论文Google引用量超过2000。

近年代表性论文 (*通讯作者):

  1. Qiushi Feng, Zehua Dong, Rongfang Nie, Xiaosheng Wang*, Identifying Diffuse Glioma Subtypes Based on Pathway Enrichment, Interdisciplinary Sciences: Computational Life Sciences, 2024, DOI: 10.1007/s12539-024-00627-w.

  2. Zijie Wu, Zehua Dong, Jiangti Luo, Weiwei Hu, Yue Tong, Xiangdong Gao, Wenbing Yao*, Hong Tian*, Xiaosheng Wang*, A comprehensive comparison of molecular and phenotypic profiles between hepatitis B virus (HBV)-infected and non-HBV-infected hepatocellular carcinoma by multi-omics analysis, Genomics, 2024, 116: 110831.

  3. Zeinab Abdelrahman*, Alaa Abdelatty, Jiangti Luo, Amy Jayne McKnight, Xiaosheng Wang*, Stratification of glioma based on stemness scores in bulk and single-cell transcriptomes, Computers in Biology and Medicine, 2024, 175: 108304.

  4. Yuehong Luo, Ting Li, Rongzhuo Long, Qinglong Guo, Libin Wei*, Xiaosheng Wang*, Exploring targets and related mechanisms of Scutellaria baicalensis for treating non-small cell lung cancer based on network pharmacology, Pharmacological Research - Modern Chinese Medicine, 2024, 10: 100381.

  5. Yin He, Xiaosheng Wang*, Identifying biomarkers associated with immunotherapy response in melanoma by multi-omics analysis, Computers in Biology and Medicine, 2023, 167: 107591.

  6. Jiali Lei, Jiangti Luo, Qian Liu, Xiaosheng Wang*, Identifying cancer subtypes based on embryonic and hematopoietic stem cell signatures in pan-cancer, Cellular Oncology, 2023, https://doi.org/10.1007/s13402-023-00886-7.

  7. Tao Yang, Qiyu Yan, Rongzhuo Long, Zhixian Liu*, Xiaosheng Wang*, PreCanCell: An Ensemble Learning Algorithm for Predicting Cancer and Non-Cancer Cells from Single-Cell Transcriptomes, Computational and Structural Biotechnology Journal, 2023, 21: 3604-3614.

  8. Hongjing Ai, Dandan Song, Xiaosheng Wang*, Defining multiple layers of intratumor heterogeneity based on variations of perturbations in multi-omics profiling, Computers in Biology and Medicine, 2023, 159: 106964.

  9. Zehua Dong, Qiyu Yan, Wenxiu Cao, Zhixian Liu, Xiaosheng Wang*, Identification of key molecules in COVID-19 patients significantly correlated with clinical outcomes by analyzing transcriptomic data, Frontiers in Immunology, 2022, 13: 930866.  

  10. Rongfang Nie, Zeinab Abdelrahman, Zhixian Liu, Xiaosheng Wang*, Evaluation of the role of vaccination in the COVID-19 pandemic based on the data from the 50 U.S. States, Computational and Structural Biotechnology Journal, 2022, 20: 4138-4145.

  11. Hongjing Ai, Rongfang Nie, Xiaosheng Wang*, Evaluation of the effects of meteorological factors on COVID-19 prevalence by the distributed lag nonlinear model, Journal of Translational Medicine, 2022, 20: 170.

  12. Dandan Song, Xiaosheng Wang*, DEPTH2: an mRNA-based algorithm to evaluate intratumor heterogeneity without reference to normal controls, Journal of Translational Medicine, 2022, 20: 150.

  13. Qian Liu, Jiali Lei, Xiaobo Zhang, Xiaosheng Wang*, Classification of Lung Adenocarcinoma Based on Stemness Scores in Bulk and Single Cell Transcriptomes, Computational and Structural Biotechnology Journal, 2022, 20: 1691-1701.

  14. Xiaojun Zhu, Shengwei Li, Jiangti Luo, Xia Ying, Zhu Li, Yuanhe Wang, Mengmeng Zhang, Tianfang Zhang, Peiyue Jiang, Xiaosheng Wang*, Subtyping of human papillomavirus-positive cervical cancers based on the expression profiles of 50 genes, Frontiers in Immunology, 2022, 13: 801639.

  15. Jiali Lei, Mengyuan Li, Xiaosheng Wang*, Predicting the development trend of the second wave of COVID-19 in five European countries, Journal of Medical Virology, 2021, 93: 5896-5907.

  16. Zeinab Abdelrahman, Qian Liu, Shanmei Jiang, Mengyuan Li, Yue Zhang, Xiaosheng Wang*, Evaluation of the current therapeutic approaches for COVID-19: a systematic review and a meta-analysis,Frontiers in Pharmacology, 2021, 12, 607408.

  17. Lin Li, Canping Chen, Xiaosheng Wang*, DITHER: an algorithm for Defining IntraTumor Heterogeneity based on EntRopy, Briefings in Bioinformatics, 2021, 22(6): 1-13.

  18. Lin Li, Xiaosheng Wang*, Identification of gastric cancer subtypes based on pathway clustering, npj Precision Oncology, 2021, 5: 46.

  19. Zeinab Abdelrahman, Zuobing Chen, Haoyu Lyu, Xiaosheng Wang*, Comparisons of the immunological landscape between COVID-19, influenza, and respiratory syncytial virus patients by clustering analysis, Computational and Structural Biotechnology Journal, 2021, 19: 2347-2355.

  20. Mengyuan Li, Xiaonan Guo, Xiaosheng Wang*, Retrospective prediction of the epidemic trend of COVID-19 in Wuhan at four phases, Journal of Medical Virology, 2021, 93: 2493–2498.

  21. Qiushi Feng, Lin Li, Mengyuan Li, Xiaosheng Wang*, Immunological Classification of Gliomas Based on Immunogenomic Profiling Journal of Neuroinflammation, Journal of Neuroinflammation, 2020, 17: 360.

  22. Mengyuan Li, Yuxiang Ma, You Zhong, Qian Liu, Canping Chen, Lei Qiang, Xiaosheng Wang*, KALRN mutations promote antitumor immunity and immunotherapy response in cancer, Journal for ImmunoTherapy of Cancer, 2020, 8: e000293.

  23. Shanmei Jiang, Yin He, Mengyuan Li, Xiaosheng Wang*, Cell cycle activity correlates with increased anti-tumor immunity in diverse cancers, Clinical and Translational Medicine, 2020, 10(2): e98.

  24. Mengyuan Li, Zhilan Zhang, Wenxiu Cao, Yijing Liu, Beibei Du, Canping Chen, Qian Liu, Md. Nazim Uddin, Shanmei Jiang, Cai Chen, Yue Zhang, Xiaosheng Wang*, Identifying novel factors associated with COVID-19 transmission and fatality using the machine learning approach, Science of The Total Environment, 2020, 764: 142810.

  25. Zhilan Zhang, Lin Li, Mengyuan Li, Xiaosheng Wang*, The SARS-CoV-2 host cell receptor ACE2 correlates positively with immunotherapy response and is a potential protective factor for cancer progression, Computational and Structural Biotechnology Journal, 2020, 18: 2438-2444.

  26. Lin Li, Qiushi Feng, Xiaosheng Wang*, PreMSIm: an R package for predicting microsatellite instability from the expression profiling of a gene panel in cancer, Computational and Structural Biotechnology Journal, 2020, 18: 668-675.

  27. Zeinab Abdelrahman, Mengyuan Li, Xiaosheng Wang*, Comparative Review of SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza A Respiratory Viruses, Frontiers in Immunology, 2020, 11: 552909.

  28. Baotao Chen, Lin Li, Mengyuan Li, Xiaosheng Wang*, HIF1A expression correlates with increased tumor immune and stromal signatures and aggressive phenotypes in human cancers, Cellular Oncology, 2020, 43(5):877-888.

  29. Yunyao Liu, Xiaoping Wang, Wenshu Li, Yujiao Xu, Yating Zhuo, Mengyuan, Yuan He, Xiaosheng Wang, Qinglong Guo, Li Zhao*, Lei Qiang*, Oroxylin A reverses hypoxia-induced cisplatin resistance through 3 inhibiting HIF-1α mediated XPC transcription, Oncogene, 2020, 39: 6893-6905.

  30. Mengyuan Li, Zhilan Zhang, Lin Li, Xiaosheng Wang*, An algorithm to quantify intratumor heterogeneity based on alterations of gene expression profiles, Communications Biology, 2020, 3: 505.

  31. Meng-Yuan Li, Lin Li, Yue Zhang, Xiao-Sheng Wang*, Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues, Infectious Diseases of Poverty, 2020, 9: 45.

  32. Wenxiu Cao, Canping Chen, Mengyuan Li, Rongfang Nie, Qiqi Lu, Dandan Song,Shengwei Li, Tao Yang, Yijing Liu, Beibei Du, Xiaosheng Wang*, Important factors affecting COVID-19 transmission and fatality in metropolises, Public Health, 2020, 190: e21-e23.

  33. Lin Li, Mengyuan Li, Xiaosheng Wang*, Cancer type-dependent correlations between TP53 mutations and antitumor immunity, DNA Repair, 2020, 88: 102785.

  34. Zehang Jiang, Zhixian Liu, Mengyuan Li, Cai Chen, Xiaosheng Wang*, Increased glycolysis correlates with elevated immune activity in tumor immune microenvironment, EBioMedicine, 2019, 42(2019): 431-442.

  35. Haoyu Lyu, Mengyuan Li, Zehang Jiang, Zhixian Liu, Xiaosheng Wang*, Correlate the TP53 Mutation and the HRAS Mutation with Immune Signatures in Head and Neck Squamous Cell Cancer, Computational and Structural Biotechnology Journal, 2019, 17: 1020-1030.

  36. Rong Fu, Chen-Feng Han, Ting Ni, Xiao-Sheng Wang, Zhao-Qiu Wu*. A ZEB1/p53 signaling axis in stromal fibroblasts promotes mammary epithelial tumours, Nature Communications, 2019, 10(1): 3210.

  37. Xiaosheng Wang*, Mengyuan Li, Correlate tumor mutation burden with immune signatures in human cancers, BMC Immunology, 2019, 20: 4.

  38. Yin He, Zehang Jiang, Cai Chen, Xiaosheng Wang*, Classification of triple-negative breast cancers based on Immunogenomic profiling, Journal of Experimental & Clinical Cancer Research, 2018, 37(1): 327.